Key result
Carbamazepine was effective in treating severe neonatal episodic laryngospasm caused by SCN4A mutations, which typically present with neonatal upper airway muscle stiffness and later myotonia.
Why the study?
Is carbamazepine effective in treating severe neonatal episodic laryngospasm due to SCN4A mutation?
Case Report (n=17)
Is carbamazepine effective in treating severe neonatal episodic laryngospasm due to SCN4A mutation?
Carbamazepine is effective for severe neonatal episodic laryngospasm caused by SCN4A mutations, expanding the known phenotype of this genetic disorder.
Answers are grounded in this paper and cite their sources.
May support carbamazepine in SCN4A myotonia; extends phenotypic series but leaves open need for controlled trials.
Carbamazepine was found to be effective on treating the disease. This case expands our understanding of the phenotype resulting from SCN4Amutations. By summarizing the characteristics of reported 16 cases in SNEL,we found they were mainly in the p.G1306E mutation. The common symptoms were upper airway muscle stiffness and feeding difficulties during neonates.When grow up, most patients have different degrees of recurrent attacks of myotonia and progressed muscle hypertrophy. Some of them have athlete-like special faces but all showed myotonic discharge in eletromyogram.
No takes yet. Share an insight, caveat, or question.
Xi et al. (2021) conducted a case report in Severe neonatal episodic laryngospasm (SNEL) due to SCN4A mutation (n=17). Carbamazepine was evaluated on Treatment effectiveness and phenotypic characteristics. Carbamazepine was effective in treating severe neonatal episodic laryngospasm caused by SCN4A mutations, which typically present with neonatal upper airway muscle stiffness and later myotonia.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: